Prostate cancer is the second cause of cancer death in men and will represent an increasing burden on European health care systems due the ageing trend of the population. Current therapies can often not prevent progression to the hormone-refractory stage, against which no efficient treatment exists. The pivotal role of the androgen receptor, also in the late phases is documented by numerous studies. A joint effort involving participants from the clinical side, academic research and industrial research is proposed to decipher the molecular mechanisms responsible for the growth and spread of prostate cancer, and identify suitable targets for the development of novel compounds for treatment of prostate cancer.
Funding SchemeCSC - Cost-sharing contracts
3015 GE Rotterdam